Haga Kazunori, Akagashi Keigo, Tobe Musashi, Uchida Kosuke, Honma Ichiya, Hirobe Emi, Ishizaki Junji, Shimizu Takashi, Nakajima Hisao, Urahama Satoshi, Sato Yoshikazu
Sanjukai Urological Hospital, Sapporo, Hokkaido, Japan.
Int J Urol. 2024 Dec;31(12):1337-1342. doi: 10.1111/iju.15558. Epub 2024 Aug 26.
The objective of our study was to assess the efficacy of Rezum, a minimally invasive surgical treatment, for patients with lower urinary tract symptoms related to benign prostatic hyperplasia (BPH) in real-world clinical practice at a single institution in Japan.
We conducted a prospective study involving 100 patients who underwent the Rezum procedure between October 2022 and February 2024. We analyzed patient backgrounds that are compliant with Japanese regulations and assessed descriptive outcomes such as symptom scores, peak flow in uroflowmetry, post-void residual (PVR) volume, and prostate volume (PVol). These data were collected at 1 and/or 3 months postoperatively.
On average, 4.7 water vapor injections were administered during the Rezum procedures, with a mean operative time of 6.3 min. Patients experienced significant relief in symptoms, with reductions of 55% in International Prostate Symptom Score, 53% in quality of life score, and 30% in Overactive Bladder Symptom Score. There was also a significant decrease in mean PVR volume (50% reduction) and PVol (27% reduction). Among the subgroup of 23 pre-interventional catheter-dependent patients, 91% achieved catheter independence.
Our single-center analysis demonstrates that Rezum is an effective and safe minimally invasive therapeutic option for patients with BPH. This promising novel technique can be particularly beneficial for patients at an augmented risk of bleeding or those considered high risk for anesthesia.
本研究的目的是在日本一家机构的实际临床实践中，评估一种微创外科治疗方法Rezum对与良性前列腺增生（BPH）相关的下尿路症状患者的疗效。
我们进行了一项前瞻性研究，纳入了2022年10月至2024年2月期间接受Rezum手术的100例患者。我们分析了符合日本法规的患者背景，并评估了描述性结果，如症状评分、尿流率峰值、排尿后残余尿量（PVR）和前列腺体积（PVol）。这些数据在术后1个月和/或3个月收集。
在Rezum手术过程中，平均进行了4.7次水蒸气注射，平均手术时间为6.3分钟。患者症状得到显著缓解，国际前列腺症状评分降低了55%，生活质量评分降低了53%，膀胱过度活动症症状评分降低了30%。平均PVR体积（降低50%）和PVol（降低27%）也有显著下降。在23例介入前依赖导尿管的患者亚组中，91%的患者不再依赖导尿管。
我们的单中心分析表明，Rezum是一种治疗BPH患者有效且安全的微创治疗选择。这种有前景的新技术对出血风险增加的患者或被认为麻醉风险高的患者可能特别有益。
